Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
Nuo Therapeutics has secured an exclusive private label distribution agreement with Smith+Nephew for the U.S. wound care market. Under this partnership, Smith+Nephew will market Nuo's Aurix System under their own brand name, CENTRIO Platelet-Rich Plasma System.
Key aspects of the agreement include:
- Five-year initial term
- Upfront distribution fee for Nuo
- Minimum purchase commitments at agreed pricing
- Potential reimbursement coverage milestone payments
Nuo will maintain manufacturing responsibilities and continue selling their Aurix brand separately, subject to customer overlap conditions. This strategic partnership leverages Smith+Nephew's market-leading position in advanced wound care to expand the adoption of autologous PRP technology for treating chronic wounds.
Nuo Therapeutics ha ottenuto un accordo esclusivo di distribuzione con marchio privato con Smith+Nephew per il mercato statunitense della cura delle ferite. In base a questa collaborazione, Smith+Nephew commercializzerà il sistema Aurix di Nuo sotto il proprio marchio, chiamato CENTRIO Platelet-Rich Plasma System.
Gli aspetti principali dell'accordo includono:
- Durata iniziale di cinque anni
- Pagamento anticipato per la distribuzione a favore di Nuo
- Impegni minimi di acquisto a prezzi concordati
- Eventuali pagamenti legati a milestone per la copertura del rimborso
Nuo manterrà la responsabilità della produzione e continuerà a vendere il proprio marchio Aurix separatamente, salvo condizioni di sovrapposizione clienti. Questa partnership strategica sfrutta la posizione di leader di Smith+Nephew nel settore avanzato della cura delle ferite per promuovere l’adozione della tecnologia PRP autologa nel trattamento delle ferite croniche.
Nuo Therapeutics ha asegurado un acuerdo exclusivo de distribución con marca privada con Smith+Nephew para el mercado estadounidense de cuidado de heridas. Bajo esta colaboración, Smith+Nephew comercializará el sistema Aurix de Nuo bajo su propia marca, llamada CENTRIO Platelet-Rich Plasma System.
Aspectos clave del acuerdo incluyen:
- Plazo inicial de cinco años
- Cuota anticipada de distribución para Nuo
- Compromisos mínimos de compra a precios acordados
- Pagos potenciales por hitos relacionados con la cobertura de reembolso
Nuo mantendrá la responsabilidad de fabricación y continuará vendiendo su marca Aurix por separado, sujeto a condiciones de superposición de clientes. Esta alianza estratégica aprovecha la posición líder de Smith+Nephew en el cuidado avanzado de heridas para impulsar la adopción de la tecnología PRP autóloga en el tratamiento de heridas crónicas.
Nuo Therapeutics는 미국 상처 치료 시장을 위해 Smith+Nephew와 독점 사설 브랜드 유통 계약을 체결했습니다. 이 파트너십에 따라 Smith+Nephew는 Nuo의 Aurix 시스템을 자사 브랜드인 CENTRIO Platelet-Rich Plasma System으로 마케팅할 예정입니다.
계약의 주요 내용은 다음과 같습니다:
- 5년 초기 계약 기간
- Nuo에 대한 선불 유통 수수료
- 합의된 가격으로 최소 구매 약속
- 보험 급여 적용 관련 마일스톤 지급 가능성
Nuo는 제조 책임을 유지하며 고객 중복 조건에 따라 Aurix 브랜드를 별도로 계속 판매할 예정입니다. 이번 전략적 파트너십은 Smith+Nephew의 첨단 상처 치료 분야 시장 선도 위치를 활용해 만성 상처 치료를 위한 자가 혈소판 풍부 혈장(PRP) 기술의 보급을 확대하는 데 목적이 있습니다.
Nuo Therapeutics a conclu un accord exclusif de distribution en marque blanche avec Smith+Nephew pour le marché américain des soins des plaies. Dans le cadre de ce partenariat, Smith+Nephew commercialisera le système Aurix de Nuo sous sa propre marque, le CENTRIO Platelet-Rich Plasma System.
Les points clés de cet accord sont :
- Durée initiale de cinq ans
- Frais de distribution versés d’avance à Nuo
- Engagements d’achats minimums à des prix convenus
- Possibilité de paiements liés à des étapes de remboursement
Nuo conservera la responsabilité de la fabrication et continuera à vendre sa marque Aurix séparément, sous réserve des conditions de chevauchement des clients. Ce partenariat stratégique tire parti de la position de leader de Smith+Nephew dans les soins avancés des plaies pour étendre l’adoption de la technologie PRP autologue dans le traitement des plaies chroniques.
Nuo Therapeutics hat eine exklusive Private-Label-Vertriebsvereinbarung mit Smith+Nephew für den US-amerikanischen Wundversorgungsmarkt abgeschlossen. Im Rahmen dieser Partnerschaft wird Smith+Nephew Nuos Aurix-System unter dem eigenen Markennamen CENTRIO Platelet-Rich Plasma System vermarkten.
Wichtige Punkte der Vereinbarung sind:
- Initiale Laufzeit von fünf Jahren
- Vorauszahlung für die Distribution an Nuo
- Mindestabnahmepflichten zu vereinbarten Preisen
- Mögliche Meilensteinzahlungen bei Erreichen von Erstattungszielen
Nuo behält die Herstellungsverantwortung und wird die Aurix-Marke weiterhin separat vertreiben, vorbehaltlich von Kundenüberschneidungen. Diese strategische Partnerschaft nutzt die marktführende Position von Smith+Nephew im Bereich der fortschrittlichen Wundversorgung, um die Verbreitung der autologen PRP-Technologie zur Behandlung chronischer Wunden zu fördern.
- Secured exclusive distribution agreement with major medical technology company Smith+Nephew
- Received upfront distribution fee from Smith+Nephew
- Guaranteed minimum purchase commitments at agreed transfer pricing
- Potential additional revenue from reimbursement coverage milestone payments
- 5-year initial term agreement provides stable long-term partnership
- Maintains manufacturing control and continues Aurix brand sales separately
- Dependent on Smith+Nephew's market performance for CENTRIO success
- Customer overlap conditions may limit Aurix direct sales potential
- Specific financial terms and minimum purchase commitments not disclosed
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement (“Agreement”) with global medical technology company Smith+Nephew (LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo’s underlying Aurix® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product. The Aurix product brand sold separately by Nuo will remain in the market under Nuo’s full control and will be fully available commercially subject to certain customer overlap conditions more fully addressed in the Agreement.
“This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo,” commented David Jorden, Nuo’s Chief Executive and Financial Officer. “We could not envision a better participant in the advanced wound care market to work with collaboratively to develop the platelet-rich plasma (PRP) market, as we believe the most important beneficiary will be patients suffering the many consequences of non-healing chronic wounds. We firmly believe Smith+Nephew’s market leading position and significant market access and development resources offer the opportunity for broader awareness and adoption of autologous PRP. We are truly honored that Smith+Nephew’s review of the available PRP products resulted in their decision to seek distribution rights to the underlying Aurix technology.”
“Smith+Nephew looks forward to providing CENTRIO PRP technology later this year to our customers, and the patients they care for, as we look to expand treatment options and advance the continuum of wound care,” said Vincent Fath, Senior Vice President and General Manager, US Advanced Wound Management. “We are pleased to be working in collaboration with Nuo as our supply partner for this exciting opportunity.”
“The path Nuo has followed since the establishment of mandated coverage for PRP in the management of chronic wounds with the 2021 National Coverage Decision has successfully brought us this point,” concluded Jorden. “We have much still to accomplish and while the market environment for advanced wound care therapies will continue to evolve, the dedicated Nuo team is eager for the opportunity. We look forward to sharing future developments and progress as we work to position Nuo for long term success.”
In exchange for Smith+Nephew’s exclusive distribution rights for CENTRIO over the initial term of five years, Nuo has received an upfront distribution fee, and will be entitled to certain minimum purchase commitments at agreed transfer pricing. Nuo will also be eligible to receive certain reimbursement coverage milestone payments subject to successful achievement of additional reimbursement coverage conditions. Additional information concerning the distribution agreement can be found in Nuo’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 1, 2025.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s receipt of distribution and reimbursement fees and minimum purchase commitments. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
Contact: David Jorden djorden@nuot.com
FAQ
What is the Smith+Nephew and AURX distribution agreement worth?
How long is the distribution agreement between Smith+Nephew and Nuo Therapeutics (AURX)?
Will Nuo Therapeutics (AURX) continue selling Aurix System after the Smith+Nephew deal?
What is Smith+Nephew's CENTRIO PRP System?
When will Smith+Nephew launch CENTRIO PRP System?
